BioTuesdays

Category - Features

RedHill readying Phase 3 trials in Crohn’s

With a PDUFA target date of Feb. 3, 2014 for its migraine drug, RHB-103, and NDA filing planned for the first quarter of 2014 for the anti-emetic drug, RHB-102, RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) is now...

Elite eyes home run in abuse-resistant technology

After reinventing itself in 2011, Elite Pharmaceuticals (OTCBB:ELTP) has bounced back with a line of generic drugs and is banking on the development of abuse-resistant opioids and once-daily opioid products to fuel its...

In conversation with Todd Wyche

As CEO and a co-founder of Brinson Patrick Securities, Todd Wyche has championed the use and growth of at-the-market offerings (ATMs) for the past 17 years for REITs, energy companies and most recently, biotech and life...

Avivagen shifts to commercial mindset from R&D

Cameron Groome, who moved into the executive suite at Avivagen (TSX-V:VIV) in March, has transformed the focus of the animal wellness company to a business and product development engine and away from an earlier...

Oramed readies oral insulin study in U.S.

Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi...

Vaxil trial validates vaccine technology

Results of a recent clinical trial of Vaxil Bio’s (TASE:VAXL) ImMucin cancer vaccine in patients with multiple myeloma has validated the company’s VaxHit technology by demonstrating safety and a strong immune response...

OnPoint’s Big-Data Equals Big Opportunity

OnPoint Medical Diagnostics (OTCQB:ONMD) is pioneering a “big-data” platform for delivering measurable, objective and automated quality assurance (QA) solutions for magnetic resonance imaging (MRI), with plans to...

Subscribe

Sign up to our weekly BioTuesdays newsletter.